Citius Oncology Reports Strong Commercial Momentum for LYMPHIR
Citus reported a 78% quarter-over-quarter increase in new institutions ordering LYMPHIR and raised revenue recognition via wholesale orders, signaling a strong commercial launch despite delayed revenue impact.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day